Antigen depot formation

Antigen depot formation is a pharmacological process rather than a single molecular target, primarily associated with the mechanism of action of vaccine adjuvants. It involves the sequestration of an antigen at the site of administration, which prevents rapid systemic clearance and degradation, thereby allowing for a slow and sustained release of the immunogen over time [1][2]. This prolonged exposure mimics a persistent infection, facilitating the continuous recruitment and activation of antigen-presenting cells (APCs), such as dendritic cells and macrophages, to the injection site [3]. While historically considered the primary mechanism for classical adjuvants like aluminum salts (alum), contemporary research suggests that depot formation often works in conjunction with the induction of local pro-inflammatory signals and the formation of 'niche' environments for immune cell interaction [4]. This mechanism is crucial for increasing the potency and longevity of the immune response in vaccines against infectious diseases and is a key strategy in the development of therapeutic cancer vaccines [5]. Safety challenges include localized tissue inflammation and the potential for chronic granulomas at the depot site [6].

Other names

Depot effectAntigen sequestrationSustained antigen releaseImmunological depot

Sustained release of antigens to prolong immune system exposure and enhance recruitment of antigen-presenting cells.